iBET and AbbVie have just enrolled in a new collaboration

Within PREDECT, Abbvie and iBET have just enrolled in a new collaboration focusing on the development and evaluation of improved in vitro / ex vivo models for lung cancer research. PREDECT is a unique European IMI-funded partnership between academic and industrial partners, aiming to develop novel, advanced and complex in vitro and in vivo models for breast, prostate and lung cancers that represent, with better fidelity, the complexity of a human tumor in situ and should lead to greater predictivity of clinical efficacy. Therefore, this recently established direct collaboration between AbbVie and iBET, alongside with other consortium partners, will address the "industrialization” of complex cell models for target validation and drug discovery. Complex models, such as 3-dimensional (3D) cultures of tumor cells together with stromal cell components, will be generated making use of bioreactor technology. This will be accompanied by a molecular pathology program where the proteomic and transcriptomic signatures of these models will be compared with human tumors, including the analysis of cellular and molecular responses to genetic perturbations or to targeted therapeutics. This depth characterization of the above men­tioned models will allow evaluation of their predictivity. Within this project there is a unique opportunity for postdoctoral fellows to work at a cutting-edge public private interphase.